A significant number of VC funds, particularly recent ones, have not been able to deliver returns to their investors. However, Swiss VC firm Redalpine stands out as an exception, which is why their newly announced $200 million seventh early-stage fund was oversubscribed.
Redalpine Capital VII, also known as RAC VII, is actively supporting 15 to 20 European early-stage companies, with nine investments already made, including German nuclear startup Proxima Fusion.
Founding partner Michael Sidler mentioned, “We completed the first close and started deploying the capital,” adding that this capital will also facilitate the opening of an office in London.
Redalpine’s consistent top quartile returns played a significant role in securing new funding. With over $1 billion in assets managed across various funds, the firm has attracted a large network of limited partners willing to reinvest based on their track record of success.
Redalpine’s investment focus aligns with current trends and market needs, attracting investors looking for deep tech opportunities in Europe. The firm’s strong network within the scientific and entrepreneurial communities gives them an edge in sourcing and supporting innovative startups.
RAC VII maintains a sector-agnostic approach, allowing Redalpine to explore opportunities in diverse sectors like energy, health, and food. This broad scope has proven beneficial in navigating market volatility and achieving successful exits in previous challenging market conditions.
With a team comprising 50% of investment professionals with scientific or engineering backgrounds, Redalpine can engage with founders on a technical level and provide operational support to portfolio companies, such as medtech startup Aktiia.
Redalpine’s expanding presence across global innovation hubs, including Silicon Valley, Berlin, Zurich, and soon London, enables them to access emerging deal flow and support promising companies like University of Cambridge spinout ExpressionEdits, which is focused on revolutionizing gene editing therapies with AI technology.
